Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Accumulated Expenses for 16 consecutive years, with $135000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 65.3% year-over-year to $135000.0, compared with a TTM value of $135000.0 through Dec 2025, down 65.3%, and an annual FY2025 reading of $135000.0, down 65.3% over the prior year.
  • Accumulated Expenses was $135000.0 for Q4 2025 at Catalyst Pharmaceuticals, down from $119.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $119.6 million in Q3 2025 and bottomed at $135000.0 in Q4 2025.
  • Average Accumulated Expenses over 5 years is $44.7 million, with a median of $45.1 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses skyrocketed 199.56% in 2023, then plummeted 99.39% in 2025.
  • Year by year, Accumulated Expenses stood at $24.3 million in 2021, then skyrocketed by 120.68% to $53.6 million in 2022, then grew by 14.28% to $61.3 million in 2023, then crashed by 99.37% to $389000.0 in 2024, then tumbled by 65.3% to $135000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for CPRX at $135000.0 in Q4 2025, $119.6 million in Q3 2025, and $107.5 million in Q2 2025.